Fondaparinux Use in Dialysis Patients

Anticoagulation Options for Dialysis

For patients requiring renal replacement therapy (RRT) without heparin-induced thrombocytopenia (HIT), unfractionated heparin or low-molecular-weight heparin are the recommended first-line anticoagulants, as suggested by the American Journal of Kidney Diseases 1
For continuous renal replacement therapy (CRRT), regional citrate anticoagulation is suggested over heparin in patients without contraindications for citrate, as recommended by the American Journal of Kidney Diseases 1
For patients with HIT requiring dialysis, argatroban or danaparoid are recommended over other non-heparin anticoagulants including fondaparinux, according to the American College of Chest Physicians 2, 3

In patients with acute or subacute HIT who require renal replacement therapy, argatroban is preferred due to its lack of renal clearance and minimal dialytic clearance, as recommended by the American College of Chest Physicians 2, 3
Argatroban has been studied in prospective trials for patients undergoing continuous renal replacement therapy with low rates of new thrombosis (0-4%) and major bleeding (0-6%), as reported by the American College of Chest Physicians 2, 6
Danaparoid can be considered as an alternative despite its renal clearance, with studies showing thrombosis rates of approximately 7% and major bleeding rates of 6%, according to the American College of Chest Physicians 2, 3

Fondaparinux has a very long half-life of 17-21 hours and relies on renal elimination, making it unsuitable for dialysis patients, as noted by the Journal of the National Comprehensive Cancer Network 4, 5
Evidence regarding the use of fondaparinux in dialysis is limited to case reports, which is insufficient to support its routine use, as stated by the American College of Chest Physicians 2, 6